Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Rang in aandelen #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Aandeelprijs
$8.74
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$699.74M
Verandering (1 dag)
-4.85%
Verandering (1 jaar)
-2.29%
Land
US
Handel BridgeBio Oncology Therapeutics Inc. (BBOT)

Categorie

Koersgeschiedenis voor BridgeBio Oncology Therapeutics Inc. (BBOT)
Hoogste slotkoers: $9.16 op 2026-08-01

Laagste slotkoers: $10.40 op 2024-02-01
Koersgeschiedenis van BridgeBio Oncology Therapeutics Inc. van 2024 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) -16.90%
2025 15.50%
2024 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH